Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was as good... Read More
New Combination Shows Early Promise in Gastric Cancer
A combo of the immuno-oncology drug Keytruda with the VEGFR-2 inhibitor Cyramza was well tolerated by gastric cancer patients in a phase... Read More
Perioperative FOLFIRINOX for Gastroesophageal Adenocarcinoma
In a trial, the chemotherapy regimen FOLFIRINOX produced response rates on par with FLOT and may be easier to tolerate, says Dan... Read More
Chemo-Refractory Gastric Cancer Treated With Toripalimab
In a trial of the investigational PD-1 antibody toripalimab, gastric cancer patients with a high tumor mutational burden showed superior overall survival... Read More
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma
Adding Tykerb to chemotherapy in HER-2 positive gastric cancer patients was proven safe in a phase 2 trial
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma
A recent study in patients with metastatic gastric cancer showed that adding docetaxel to a modified FOLFOX7 chemo regimen produced a response... Read More
CAR T Cells Show Activity in Solid Tumors
Gastric cancer patients in a trial responded to a CAR-T therapy targeting a molecule found in epithelial cells called claudin 18.2. Additional... Read More
Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer
What are the takeaways from recent mixed trial results for Keytruda in gastric cancer? Dr. Mark Zalupski of University of Michigan weighs... Read More
Perioperative Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs Fluorouracil or Capecitabine + Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or GE Junction Adenocarcinoma
A phase II/III trial investigated a chemotherapy triplet, FLOT (docetaxel, oxaliplatin, 5-FU/LV), as perioperative therapy in resectable gastroesophageal cancers compared with ECF/ECX,... Read More
Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
A new phase 3 trial of Bemarituzumab for patients with advanced gastric cancer is open for enrollment. Curious about clinical trials? Use... Read More